Picture of MyndTec logo

MYTC MyndTec Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-45.69%
3m-72.71%
6m+59.06%
1yr-71.55%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-1087.83%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of MyndTec EPS forecast chart

Profile Summary

MyndTec Inc. is a medical technology company. The Company is engaged in developing neurological treatment and rehabilitation technologies, including the MyndLink artificial intelligence (AI)-powered software platform, which is being developed to optimize neurostimulation therapies. The Company intends to focus its use of MyndLink on improving patient selection and outcomes for chronic pain treatments like spinal cord stimulation. It also offers MyndMove, which is a non-invasive functional electrical stimulation (FES) therapy designed to improve voluntary arm and hand function in patients with upper-limb paralysis, such as those suffering from stroke or spinal cord injury (SCI). The Company’s cell regeneration technology, which is in preclinical study, uses patients' own neural stem cells, guided by electrical stimulation, to support brain tissue repair and potentially improve outcomes in neurological conditions such as Parkinson’s, stroke, and Alzheimer’s.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    September 30th, 2024
    Incorporated
    June 10th, 2008
    Public Since
    February 24th, 2022
    No. of Employees
    7
    Sector
    Healthcare Equipment & Supplies
    Industry
    Healthcare
    Exchange
    ca flag iconCanadian Securities Exchange
    Shares in Issue
    25,535,734

    MYTC Share Price Performance

    Similar to MYTC

    Picture of Aquarius Surgical Technologies logo

    Aquarius Surgical Technologies

    ca flag iconCanadian Securities Exchange

    Picture of Cannabix Technologies logo

    Cannabix Technologies

    ca flag iconCanadian Securities Exchange

    Picture of Cognetivity Neurosciences logo

    Cognetivity Neurosciences

    ca flag iconCanadian Securities Exchange

    Picture of Diagnostear Technologies logo

    Diagnostear Technologies

    ca flag iconCanadian Securities Exchange

    Picture of Gemina Laboratories logo

    Gemina Laboratories

    ca flag iconCanadian Securities Exchange

    FAQ